Corvus Pharmaceuticals, Inc.

CRVS · NASDAQ
Analyze with AI
9/30/2025
6/30/2025
3/31/2025
12/31/2024
Operating Activities
Net Income-$10-$8$15-$12
Dep. & Amort.$0$0$0$0
Deferred Tax$0$0$0$0
Stock-Based Comp.$0$1$1$1
Change in WC-$1$3$0-$1
Other Non-Cash$1-$2-$25$4
Operating Cash Flow-$10-$6-$8-$8
Investing Activities
PP&E Inv.$0-$0-$0$0
Net Acquisitions$0$0$0$0
Inv. Purchases-$31-$39-$8-$20
Inv. Sales/Matur.$29$19$12$14
Other Inv. Act.$0$0$0$0
Investing Cash Flow-$3-$20$4-$6
Financing Activities
Debt Repay.$0$0$0$0
Stock Issued$0$36$0$19
Stock Repurch.$0$0$0$0
Dividends Paid$0$0$0$0
Other Fin. Act.$0$0$0$0
Financing Cash Flow$0$36$0$19
Forex Effect$0$0$0$0
Net Chg. in Cash-$12$10-$4$4
Supplemental Information
Beg. Cash$15$5$9$5
End Cash$3$15$5$9
Free Cash Flow-$10-$6-$8-$8
Corvus Pharmaceuticals, Inc. (CRVS) Financial Statements & Key Stats | AlphaPilot